MedTrace Logo

Efficacy and Safety of Firebird 2 Stent in Treatment of Complex Coronary Lesions in Diabetes

NCT01257373 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1300

Last updated 2010-12-30

No results posted yet for this study

Summary

The goal of this study is to assess the long-term efficacy and safety of Firebird2 Cobalt-Chromium（CoCr）-alloyed sirolimus-eluting stent in treatment of complex lesions in diabetes.

Conditions

Interventions

DEVICE

Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent

Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.

Sponsors & Collaborators

  • Air Force Military Medical University, China

    collaborator OTHER

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER

  • Shanghai MicroPort Medical (Group) Co., Ltd.

    collaborator INDUSTRY

  • CCheart Consulting Co., Ltd.

    collaborator INDUSTRY

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Haichang Wang, MD，PhD · Department of cardiology of Xijing Hospital, Fourth Military Medcical Univercsity

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-04-30
Completion
2013-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01257373 on ClinicalTrials.gov